Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

222 Press Releases
DateTitleCompany
26 Apr 17 Shire Granted EU Conditional Marketing Authorisation for Natpar[®?] (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism Shire plc,
Published by
PR Newswire
26 Apr 17 Shire Granted EU Conditional Marketing Authorisation for Natpar[®?] (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism Shire plc,
Published by
PR Newswire
26 Apr 17 Shire Granted EU Conditional Marketing Authorisation for Natpar[®?] (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism Shire plc,
Published by
PR Newswire
26 Apr 17 Shire Granted EU Conditional Marketing Authorisation for Natpar[®?] (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism Shire plc,
Published by
PR Newswire
25 Apr 17 Shire to Participate at the Deutsche Bank 42nd Annual Health Care Conference Shire ,
Published by
PharmiWeb.com
25 Apr 17 Shire to Participate at the Deutsche Bank 42nd Annual Health Care Conference Shire plc,
Published by
PR Newswire
24 Apr 17 Shire Launches #PIPostsThanks Social Campaign to Raise Awareness of Primary Immunodeficiency (PI) Shire plc,
Published by
PR Newswire
17 Apr 17 Shire plc: Data Show A Bleeding Episode Occurs Every Three to 15 Seconds in People Living With Hemophilia Worldwide Shire plc,
Published by
PR Newswire
30 Mar 17 INTUNIV® (Guanfacine Hydrochloride Prolonged Release), a Non-stimulant for the Treatment of ADHD, Receives Approval in Japan Shire ,
Published by
PharmiWeb.com
23 Mar 17 Shire Receives FDA Fast Track Designation for Recombinant ADAMTS13 (SHP655) for Treatment of Hereditary Thrombotic Thrombocytopenic Purpura Shire ,
Published by
PharmiWeb.com
23 Mar 17 SHIRE RECEIVES FDA FAST TRACK DESIGNATION FOR RECOMBINANT ADAMTS13 (SHP655) FOR TREATMENT OF HEREDITARY THROMBOTIC THROMBOCYTOPENIC PURPURA SHIRE ,
Published by
PharmiWeb.com
07 Mar 17 CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative to Patients’ Previous Immunoglobulin Therapy Shire ,
Published by
PharmiWeb.com
01 Mar 17 Shire to Participate at the Cowen 37th Annual Healthcare Conference Shire plc,
Published by
PR Newswire
27 Feb 17 CHMP Recommends EU Conditional Marketing Authorisation for Natpar® (Parathyroid Hormone) for Patients with Chronic Hypoparathyroidism Shire ,
Published by
PharmiWeb.com
23 Feb 17 New England Journal of Medicine Publishes Phase 1b Results for Shire's Investigational Treatment for Hereditary Angioedema, a Rare Genetic Disease Shire,
Published by
PharmiWeb.com
23 Feb 17 Shire Launches 'Rare Count' Campaign to Personalize the Global Impact of Rare Diseases Shire ,
Published by
PharmiWeb.com
19 Jan 17 U.S. FDA Acknowledges Receipt of Shire's New Drug Application for SHP465 for ADHD Shire plc,
Published by
PR Newswire
02 Dec 16 Topline Results of Phase 3 Investigational Study of VONVENDI™ [von Willebrand factor (recombinant)] Meets Primary Endpoint Effectively Controlling Bleeding and Blood Loss During Surgical Procedures Shire plc,
Published by
PR Newswire
16 Nov 16 Shire Launches CUVITRU[TM] [Immune Globulin Subcutaneous (Human), 20% Solution] in the U.S. for Primary Immunodeficiency Shire plc,
Published by
PR Newswire
22 Nov 16 Shire to Establish Rare Disease Innovation Hub in Cambridge, Mass. Shire plc,
Published by
PR Newswire
02 Dec 16 Topline Results of Phase 3 Investigational Study of VONVENDI™ [von Willebrand factor (recombinant)] Meets Primary Endpoint Effectively Controlling Bleeding and Blood Loss During Surgical Procedures Shire plc,
Published by
PR Newswire
02 Dec 16 Topline Results of Phase 3 Investigational Study of VONVENDI™ [von Willebrand factor (recombinant)] Meets Primary Endpoint Effectively Controlling Bleeding and Blood Loss During Surgical Procedures Shire plc,
Published by
PR Newswire
02 Dec 16 Topline Results of Phase 3 Investigational Study of VONVENDI™ [von Willebrand factor (recombinant)] Meets Primary Endpoint Effectively Controlling Bleeding and Blood Loss During Surgical Procedures Shire plc,
Published by
PR Newswire
31 Oct 16 Shire announces recipients of 2016 Excellence in ADHD Patient Group Awards Shire ,
Published by
PharmiWeb.com
12 Nov 16 Tolerability Data for Shire's CUVITRU Accepted for Oral Presentation at the American College Of Allergy, Asthma & Immunology Annual Meeting Shire plc,
Published by
PR Newswire
10 Nov 16 Shire's Investor Day Showcases Strength of Rare Disease Pipeline and Commercial Portfolio Shire plc,
Published by
PR Newswire
16 Nov 16 Shire Launches CUVITRU[TM] [Immune Globulin Subcutaneous (Human), 20% Solution] in the U.S. for Primary Immunodeficiency Shire plc,
Published by
PR Newswire
16 Nov 16 Shire Launches CUVITRU[TM] [Immune Globulin Subcutaneous (Human), 20% Solution] in the U.S. for Primary Immunodeficiency Shire plc,
Published by
PR Newswire
16 Nov 16 Shire Launches CUVITRU[TM] [Immune Globulin Subcutaneous (Human), 20% Solution] in the U.S. for Primary Immunodeficiency Shire plc,
Published by
PR Newswire
22 Nov 16 Shire to Establish Rare Disease Innovation Hub in Cambridge, Mass. Shire ,
Published by
PharmiWeb.com
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.